The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: Evidence from 19 case-control studies

Abstract

The potentially functional polymorphism, rs763110 (-844C>T), in the promoter region of the FAS ligand (FASL) gene, has been implicated in cancer risk, but individually published studies show inconclusive results. To derive a more precise estimation of the association between the FASL rs763110 and risk of cancer, we performed a meta-analysis of 19 published studies that included 11105 cancer cases and 11372 controls. We used odds ratios (ORs) and 95% confidence intervals (CIs) to assess the strength of the associations. Overall, the rs763110 CT and TT variant genotypes were associated with a significantly reduced cancer risk of all cancer types in different genetic models (homozygote comparison: OR=0.80, 95% CI: 0.68-0.95, Pheterogeneity=0.001; heterozygote comparison: OR=0.82, 95% CI: 0.72-0.95, Pheterogeneity <0.001; dominant model comparison: OR=0.82, 95% CI: 0.71-0.94, Pheterogeneity <0.001; and recessive model comparison: OR=0.88, 95% CI: 0.81-0.96, Pheterogeneity =0.074). In the stratified analyses, the risk remained for studies of the smoking-related cancers and Asian populations, or population-based studies in all the genetic models. Although some modest bias could not be eliminated, this meta-analysis suggests that the FASL rs763110 T allele has a possible protective effect on cancer risk.